Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
-
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
-
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
-
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
-
BUSINESS MTPC to Focus on Development of Global Human Resources
December 14, 2011
-
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
-
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
-
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
-
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
-
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
-
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
-
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
-
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
-
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
-
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
-
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
-
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
-
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
-
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
-
REGULATORY CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…